Literature DB >> 16310260

Effects of carvedilol on cardiac cytokines expression and remodeling in rat with acute myocardial infarction.

Bin Li1, Yu-Hua Liao, Xiang Cheng, Hongxia Ge, Heping Guo, Min Wang.   

Abstract

OBJECTIVE: A number of observations suggest that cytokines may be important modulators in the ventricular remodeling process. It is unclear whether carvedilol modulates myocardial pro-inflammatory and anti-inflammatory cytokines expression. We hypothesized that carvedilol could improve ventricular remodeling partly through the modulation of cytokines. The goal of this study was to evaluate the effects of carvedilol on cardiac cytokines expression as well as on myocardial and extracellular matrix remodeling in rats with acute myocardial infarction.
METHODS: Rats with AMI induced by left anterior descending branch ligation were randomized to carvedilol and control group which were further compared to sham-operated group. We studied the effects of 4-weeks therapy with carvedilol starting 24 h after infarction on 1) hemodynamics, 2) tissue weights, 3) myocardial cytokines (TNF-alpha, IL-1beta, IL-6, IL-10 and TGF-beta1) expression by semi-quantitative RT-PCR and immunoblotting, 4) matrix metalloproteinases activity by gelatin zymography, 5) collagen expression by immunohistochemistry, 6) myocardium fetal gene (alpha and beta myosin heavy chain) expression.
RESULTS: Treatment with carvedilol 1) reduced the pro-inflammatory cytokines and fibrogenic cytokine TGF-beta1 levels in myocardium and was associated with the amelioration of the elevated left ventricular diastolic pressure. 2) increased anti-inflammatory cytokine, IL-10 protein expression. 3) reduced matrix metalloproteinases-2 and matrix metalloproteinases-9 activity 4) reduced myocardial collagens 5) did not modify fetal gene re-expression.
CONCLUSION: Pro-inflammatory, anti-inflammatory and fibrogenic cytokines are all involved in the process of post-infarction myocardial remodeling. One mechanism underlying the beneficial effects of carvedilol on post-infarction myocardial remodeling may be modulation of the balance between pro- and anti-inflammatory cytokines as well as fibrogenic cytokines and extracellular matrix (ECM) remodeling.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16310260     DOI: 10.1016/j.ijcard.2005.08.065

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  15 in total

1.  Anti-inflammatory activities of hepatocyte growth factor in post-ischemic heart failure.

Authors:  Shu-Ling Rong; Xiao-Lin Wang; Yi-Cheng Wang; Huan Wu; Xue-Dong Zhou; Ze-Kun Wang; Yu-Chuan Wang; Cun-Shui Xue; Bao Li; Dong-Lai Gao
Journal:  Acta Pharmacol Sin       Date:  2018-05-24       Impact factor: 6.150

Review 2.  Possible indications of beta-blockers in the perioperative period other than prevention of cardiac ischemia.

Authors:  Yuji Kadoi; Shigeru Saito
Journal:  J Anesth       Date:  2010-02       Impact factor: 2.078

3.  Anti-inflammatory and pro-angiogenic effects of beta blockers in a canine model of chronic ischemic cardiomyopathy: comparison between carvedilol and metoprolol.

Authors:  D Elizabeth Le; Marco Pascotto; Howard Leong-Poi; Ibrahim Sari; Antonio Micari; Sanjiv Kaul
Journal:  Basic Res Cardiol       Date:  2013-09-27       Impact factor: 17.165

4.  Impact of proteasome inhibitor MG-132 on expression of NF-κB, IL-1β and histological remodeling after myocardial infarction.

Authors:  Xinhua Wu; Zhangrong Chen; Ying Yang; Yu Dong; Hong Liu; Shiquan Kuang; Kailiang Luo
Journal:  Exp Ther Med       Date:  2018-06-13       Impact factor: 2.447

5.  Rac-induced left ventricular dilation in thyroxin-treated ZmRacD transgenic mice: role of cardiomyocyte apoptosis and myocardial fibrosis.

Authors:  Mohammad T Elnakish; Mohamed D H Hassona; Mazin A Alhaj; Leni Moldovan; Paul M L Janssen; Mahmood Khan; Hamdy H Hassanain
Journal:  PLoS One       Date:  2012-08-24       Impact factor: 3.240

6.  Carvedilol-Afforded Protection against Daunorubicin-Induced Cardiomyopathic Rats In Vivo: Effects on Cardiac Fibrosis and Hypertrophy.

Authors:  Wawaimuli Arozal; Flori R Sari; Kenichi Watanabe; Somasundaram Arumugam; Punniyakoti T Veeraveedu; Meilei Ma; Rajarajan A Thandavarayan; Vijayakumar Sukumaran; Arun Prasath Lakshmanan; Yoshiyasu Kobayashi; Sayaka Mito; Vivian Soetikno; Kenji Suzuki
Journal:  ISRN Pharmacol       Date:  2011-04-14

7.  Potential Role of Carvedilol in the Cardiac Immune Response Induced by Experimental Infection with Trypanosoma cruzi.

Authors:  Aline Luciano Horta; Ana Luisa Junqueira Leite; G Paula Costa; Vivian Paulino Figueiredo; André Talvani
Journal:  Biomed Res Int       Date:  2017-03-09       Impact factor: 3.411

8.  Carvedilol decrease IL-1β and TNF-α, inhibits MMP-2, MMP-9, COX-2, and RANKL expression, and up-regulates OPG in a rat model of periodontitis.

Authors:  Raimundo Fernandes de Araújo Júnior; Tatiana Oliveira Souza; Caroline Addison Xavier de Medeiros; Lélia Batista de Souza; Maria de Lourdes Freitas; Hévio Freitas de Lucena; Maria do Socorro Costa Feitosa Alves; Aurigena Antunes de Araújo
Journal:  PLoS One       Date:  2013-07-03       Impact factor: 3.240

9.  Effect of carvedilol on cardiomyocyte apoptosis in a rat model of myocardial infarction: a role for toll-like receptor 4.

Authors:  Qingwei Liu; Jianhua Zhang; Yan Xu; Ying Huang; Changhao Wu
Journal:  Indian J Pharmacol       Date:  2013 Sep-Oct       Impact factor: 1.200

10.  Smad3 inactivation and MiR-29b upregulation mediate the effect of carvedilol on attenuating the acute myocardium infarction-induced myocardial fibrosis in rat.

Authors:  Jie-Ning Zhu; Ren Chen; Yong-Heng Fu; Qiu-Xiong Lin; Shuai Huang; Lin-Lin Guo; Meng-Zhen Zhang; Chun-Yu Deng; Xiao Zou; Shi-Long Zhong; Min Yang; Jian Zhuang; Xi-Yong Yu; Zhi-Xin Shan
Journal:  PLoS One       Date:  2013-09-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.